rosiglitazone has been researched along with osteoprotegerin in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| An, JJ; Han, DH; Kim, DM; Kim, SH; Lee, EJ; Lim, SK; Rhee, Y | 1 |
| Gram, J; Henriksen, JE; Juhl, HF; Nybo, M; Olesen, M; Preil, SR; Rasmussen, LM; Yderstraede, K | 1 |
| Bookout, AL; Dechow, PC; Ding, X; Dutchak, PA; Gerard, RD; Goetz, R; Kliewer, SA; Mangelsdorf, DJ; Mohammadi, M; Wan, Y; Wang, X; Wei, W | 1 |
| Asuncion, F; Boyce, R; Chen, MM; Chinookoswong, N; Dwyer, D; Han, CY; Ke, HZ; Li, X; Liu, B; Niu, QT; Ominsky, MS; Stanislaus, S; Stolina, M; Véniant, MM; Villasenor, K; Wang, J; Wong, P; Xu, J | 1 |
1 trial(s) available for rosiglitazone and osteoprotegerin
| Article | Year |
|---|---|
Rosiglitazone decreases plasma levels of osteoprotegerin in a randomized clinical trial with type 2 diabetes patients.
Topics: Adult; Aged; Biomarkers; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Osteoprotegerin; Rosiglitazone; Thiazolidinediones; Treatment Outcome | 2011 |
3 other study(ies) available for rosiglitazone and osteoprotegerin
| Article | Year |
|---|---|
Expression and regulation of osteoprotegerin in adipose tissue.
Topics: 3T3-L1 Cells; Adipocytes; Adipogenesis; Adipose Tissue; Animals; Cell Differentiation; Gene Expression Regulation; Hypoglycemic Agents; Insulin; Male; Mice; Osteoprotegerin; RANK Ligand; Rats; Rats, Sprague-Dawley; Rosiglitazone; Thiazolidinediones; Transfection; Tumor Necrosis Factor-alpha | 2007 |
Fibroblast growth factor 21 promotes bone loss by potentiating the effects of peroxisome proliferator-activated receptor γ.
Topics: Adipogenesis; Animals; Bone and Bones; Bone Marrow; Bone Resorption; Drug Resistance; Fibroblast Growth Factors; Humans; Mice; Mice, Knockout; Organ Size; Osteoblasts; Osteogenesis; Osteoprotegerin; PPAR gamma; RANK Ligand; Rosiglitazone; Thiazolidinediones | 2012 |
FGF21 Is Not a Major Mediator for Bone Homeostasis or Metabolic Actions of PPARα and PPARγ Agonists.
Topics: Animals; Bone Density; Dietary Fats; Fibroblast Growth Factors; Gene Expression Regulation; Glucose; Homeostasis; Humans; Insulin; Male; Mice; Mice, Knockout; Obesity; Osteoprotegerin; PPAR alpha; PPAR gamma; RANK Ligand; Rosiglitazone; Thiazolidinediones | 2017 |